(0.75%) 5 166.43 points
(0.38%) 38 824 points
(0.83%) 16 291 points
(0.42%) $78.44
(2.43%) $2.19
(1.09%) $2 333.70
(3.66%) $27.67
(0.05%) $965.80
(-0.06%) $0.928
(-0.45%) $10.82
(-0.17%) $0.796
(-0.10%) $91.36
Live Chart Being Loaded With Signals
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials...
Stats | |
---|---|
今日成交量 | 5.29M |
平均成交量 | 3.14M |
市值 | 15.69B |
EPS | HKD0 ( 2023-08-10 ) |
Last Dividend | HKD0.140 ( 2023-06-09 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 8.30 |
ATR14 | HKD0.00200 (0.04%) |
音量 相关性
China Grand 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
China Grand 相关性 - 货币/商品
China Grand 财务报表
Annual | 2023 |
营收: | HKD10.53B |
毛利润: | HKD6.52B (61.96 %) |
EPS: | HKD0.540 |
FY | 2023 |
营收: | HKD10.53B |
毛利润: | HKD6.52B (61.96 %) |
EPS: | HKD0.540 |
FY | 2022 |
营收: | HKD9.56B |
毛利润: | HKD5.95B (62.24 %) |
EPS: | HKD0.590 |
FY | 2021 |
营收: | HKD8.60B |
毛利润: | HKD5.25B (61.03 %) |
EPS: | HKD0.677 |
Financial Reports:
No articles found.
China Grand Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.140 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0860 | 2019-06-12 |
Last Dividend | HKD0.140 | 2023-06-09 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | HKD0.542 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.33 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.28 | |
Div. Directional Score | 9.28 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9600.HK | No Dividend Player | 2023-06-14 | Insufficient data to determine frequency | 0 | 0.00% | |
2107.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
1113.HK | Ex Dividend Knight | 2023-09-04 | Semi-Annually | 0 | 0.00% | |
0175.HK | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
3813.HK | Ex Dividend Junior | 2023-09-12 | Sporadic | 0 | 0.00% | |
1692.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
0722.HK | Ex Dividend Knight | 2023-12-05 | Semi-Annually | 0 | 0.00% | |
2283.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1268.HK | Ex Dividend Knight | 2023-09-20 | Semi-Annually | 0 | 0.00% | |
0317.HK | Ex Dividend Junior | 2023-05-29 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.179 | 1.500 | 6.43 | 9.64 | [0 - 0.5] |
returnOnAssetsTTM | 0.0835 | 1.200 | 7.22 | 8.66 | [0 - 0.3] |
returnOnEquityTTM | 0.127 | 1.500 | 9.70 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.264 | -1.000 | 7.36 | -7.36 | [0 - 1] |
currentRatioTTM | 1.224 | 0.800 | 8.88 | 7.10 | [1 - 3] |
quickRatioTTM | 0.843 | 0.800 | 9.75 | 7.80 | [0.8 - 2.5] |
cashRatioTTM | 0.239 | 1.500 | 9.78 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.148 | -1.500 | 7.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 12.98 | 1.000 | 6.30 | 6.30 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.636 | 2.00 | 9.79 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.494 | 2.00 | 9.75 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.221 | -1.500 | 9.12 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.620 | 1.000 | 3.01 | 3.01 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.253 | 1.000 | 6.94 | 6.94 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.667 | 1.000 | 7.41 | 7.41 | [0.2 - 2] |
assetTurnoverTTM | 0.468 | 0.800 | -0.216 | -0.172 | [0.5 - 2] |
Total Score | 12.28 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.34 | 1.000 | 9.26 | 0 | [1 - 100] |
returnOnEquityTTM | 0.127 | 2.50 | 9.81 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.494 | 2.00 | 9.84 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.13 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.636 | 2.00 | 9.79 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.264 | 1.500 | 7.36 | -7.36 | [0 - 1] |
pegRatioTTM | 0.136 | 1.500 | -2.43 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.212 | 1.000 | 7.21 | 0 | [0.1 - 0.5] |
Total Score | 6.28 |
China Grand
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices. In addition, the company offers biotechnology and health products, such as Taurine, amino acid products, steroid products, and bio-pesticides and agricultural antibiotics; and specialized pharmaceutical raw materials and other products, including metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, nitromethane, etc. Further, the company offers agrochemicals, fine chemicals, and chemical medicines; ophthalmic gel and eye drops; steroid hormones active pharmaceutical ingredients and related intermediates; bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. Grand Pharmaceutical Group Limited has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited and changed its name to Grand Pharmaceutical Group Limited in November 2021. Grand Pharmaceutical Group Limited was incorporated in 1995 and is based in Central, Hong Kong.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。